November 10, 2025 — Leads & Copy — Guardant Health, Inc. has expanded its Guardant Reveal® blood test to include late-stage therapy response monitoring for patients with solid tumors.
The Guardant Reveal blood test tracks over 20,000 epigenomic (methylation) signals to measure changes in circulating tumor DNA (ctDNA) levels in a patient’s blood. This allows for the prediction of outcomes sooner than imaging, and without the need for a tissue sample.
The expanded offering builds on Reveal’s performance in minimal residual disease (MRD) detection, and leverages Guardant’s proprietary epigenomic technology powered by the Guardant Infinity Smart Platform. It is designed to predict therapy response across all therapy classes, including immunotherapy and chemotherapy.
Guardant Reveal therapy response monitoring can be initiated at any point during a patient’s treatment, providing clinicians with flexibility and actionable insights within seven days.
Helmy Eltoukhy, Guardant Health Chairman and co-CEO, said that Guardant Reveal continues to redefine what’s possible in liquid biopsy for oncologists and patients, creating a new paradigm for therapy monitoring. Eltoukhy added that integrating therapy response monitoring into Guardant Reveal creates an end-to-end monitoring test built on the Infinity Smart Platform. This simplifies clinical workflows and empowers providers to make faster, more informed decisions with just a simple blood draw, Eltoukhy said.
Recent clinical evidence also supports the expansion of Guardant Reveal to late-stage therapy response monitoring. The first clinical-validation study of pan-cancer chemotherapy monitoring, published last week in The Journal of Liquid Biopsy, showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.
In addition, findings from the RADIOHEAD study, a large clinical validation study focused on immune checkpoint inhibitor response monitoring across multiple solid tumor types, showed Guardant Reveal successfully detected responses to immunotherapy up to 5 months earlier than standard imaging. Decreases in tumor fraction were also strongly associated with improved patient outcomes, according to the study.
A new universal ordering option that launched today will allow physicians to order Guardant’s comprehensive portfolio of products in a single click. This is designed to provide physicians with more flexibility and reduce administrative burden to support seamless patient management from diagnosis through all stages of treatment.
Guardant Health was founded in 2012 and is focused on guarding wellness and giving every person more time free from cancer. The company transforms patient care and accelerates new cancer therapies by providing insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests are designed to help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
This press release contains forward-looking statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays. These statements involve risks and uncertainties that could cause actual results to differ from anticipated results. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ because of a number of factors.
These and additional risks and uncertainties are discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission.
The forward-looking statements in this press release are based on information available to Guardant Health as of November 10, 2025, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to November 10, 2025.
Source: Guardant Health
